CLINICAL TRIALS PROFILE FOR DESOXIMETASONE
✉ Email this page to a colleague
All Clinical Trials for desoximetasone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01018134 ↗ | Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study | Completed | Taro Pharmaceuticals USA | Phase 2 | 2009-11-01 | The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis. |
NCT01043393 ↗ | Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study | Completed | Taro Pharmaceuticals USA | Phase 2 | 2010-02-01 | The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile. |
NCT01206387 ↗ | Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis | Completed | Taro Pharmaceuticals USA | Phase 3 | 2010-08-01 | efficacy study in patients with moderate to severe plaque psoriasis. |
NCT01206660 ↗ | Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis | Completed | Taro Pharmaceuticals USA | Phase 3 | 2010-08-01 | The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis. |
NCT02340169 ↗ | Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis | Completed | Taro Pharmaceuticals USA | Phase 4 | 2015-01-23 | The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile. |
NCT02595073 ↗ | Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis | Completed | Taro Pharmaceuticals USA | Phase 3 | 2015-09-04 | Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for desoximetasone
Condition Name
Clinical Trial Locations for desoximetasone
Trials by Country
Clinical Trial Progress for desoximetasone
Clinical Trial Phase
Clinical Trial Sponsors for desoximetasone
Sponsor Name